Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220646 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
A Phase 2 study of Brain Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT03220646 is a Phase 2 study of Brain Tumor that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (77% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT03220646, a Phase 2 study of Brain Tumor, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
Conditions Studied
Interventions
- DRUG abemaciclib
Study Locations (8)
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Connecticut
- Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only) - Hartford
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220646
The ClinicalTrials.gov registry entry for NCT03220646 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (77% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which abemaciclib is the first listed.
NCT03220646 reports 8 study locations spanning 4 distinct geographic areas - top geographies include New Jersey, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03220646 about?
NCT03220646 is a clinical study titled "Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors". The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
What is the current status of trial NCT03220646?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-07-13. Estimated completion is 2026-07.
What conditions does trial NCT03220646 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT03220646?
The interventions under investigation include: abemaciclib (DRUG).
Who is sponsoring clinical trial NCT03220646?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03220646 being conducted?
This trial has 8 study locations across Connecticut, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
COMPLETED · Phase 2
-
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.